Many disorders require multi-component dynamic treatment regimes given sequentially in time to achieve and maintain good outcomes.
Introduction
Dynamic treatment regimes (Robins, 1986 (Robins, , 1987 Lisziewicz and Lori, 2002) . These regimes individualize the treatment level and type via decision rules that input patient outcomes collected during treatment and output recommended treatment alterations. Dynamic treatment regimes (DTR) are attractive to clinical scientists because they operationalize the clinical practice of adapting and reevaluating treatment options based on patient progress. DTR's are also often multicomponent (i.e., multiple factor) treatments: components may include treatments (counseling, medications), adjunctive treatments, different delivery mechanisms and different intensities of treatment. The focus of this article is on screening experiments for dynamic treatment regimes. As described in Dean and Lewis (2006) the primary purpose of a screening experiment is to reduce the number of components that need be considered in future experimental trials. These are not confirmatory experiments in that they are not intended to result in a single best multi-component DTR but rather they should result in several potential promising DTR's. This formulation and analysis of screening experiments for multi-component DTRs requires the combination of ideas from causal inference, multistage decision theory and factorial experimental design.
Consider two treatment stages for each subject; at the jth stage one provides a treatment combination corresponding to a vector of factor (e.g. component) levels, A j . A DTR specifies how to select the treatment combination by a sequence of decision rules, one per stage, {d 1 This work is motivated by research in mental health and substance abuse. In these areas, the complexity of the disorders combined with the heterogeneity in treatment response forces researchers to consider multi-factorial sequences of treatments. Presently such dynamic treatment regimes are constructed via expert opinion and then tested in randomized two-arm trials. One factor at a time studies are also conducted. Subsequent to these trials, investigators take advantage of variation in treatment receipt (eg. due to nonadherence or subjects seeking different amounts and combinations of factor levels) to conduct observational analyses to improve the dynamic treatment regime. As is well known such analyses are subject to bias due to uncontrolled causal confounding. A natural alternate which reduces this confounding is to use experimental ideas from the field of design of experiments.
In the construction of a dynamic treatment regime, there are often initially many possible candidate factors (i.e., A j may be of dimension up to 5 or 6). Using ideas from the design of experiments field, a sequence of experiments would be used to inform the construction of the DTR. The first of which is a screening experiment where the goal is to identify the most active factors and screen out the less active fac-tors. See Montgomery and Jennings (2006) for a introductory discussion of screening experiments in industrial settings.
As stated above this work is motivated by trials in substance abuse, mental health and HIV research. Unfortunately, in these settings the classical design and analysis of screening experiments cannot be directly imported. This is because some stage 2 factors are only relevant for patients who responded (or did not respond) to prior stage 1 treatment factors. As will be seen this implies that the classical definitions of main and interaction effects among stage 1 factors (say via an ANOVA decomposition) do not have causal content. We define causal main and interaction effects in Section 2. Somewhat surprisingly, it turns out that we are able to utilize experimental designs that, although they cannot be strictly called "full" or "balanced" fractional factorial designs, continue to share some of the nice properties of traditional screening designs. Most importantly, the designs permit one to evaluate the causal effects and thus screen factors. We develop analysis methods for these designs. In Section 3, we provide the means to ascertain the aliasing of the causal effects associated with the designs. Section 4 provides examples illustrating a variety of designs. In the Section 5 a simulation study is used to evaluate the robustness of the proposed method. Section 6 concludes with summary and discussion of open problems.
Causal Main and Interaction Effects of the Factors
Screening factors traditionally occurs via the assessment of main and interaction effects in ANOVA decompositions (see Wu and Hamada, 2000 or Montgomery and Jennings, 2006) for the conditional mean of the primary outcome. However, in our setting the effects defined by the usual ANOVA decomposition are problematic. To see why special care is required in defining effects, consider a simple setting where there is only one stage 1 factor and two stage 2 factors. Each factor takes on levels in {−1, 1}. Suppose N subjects are each randomized equally to the two levels of the stage one factor A 1 . Then an indicator of early response is observed; R is 1 if the subject is responding following assignment of A 1 and 0 otherwise (there is no O 1 and O 2 = R). At stage 2 the subject with R = 1 is randomized equally between the {−1, 1} levels of A (1) 2 , and if R = 0, the subject is randomized equally between the {−1, 1} levels of A (0) 2 . For simplicity, we refer to individuals with R = 1, 0 as responders, non-responders, respectively. For example in stage 1, the factor may be "medication" and each level might correspond to one of two possible first line medications; the stage 2 factor for non-responders might be "medication" as well but here the two levels might correspond to "augment medication" or "switch medication." The stage 2 factor for early responders might be called "maintenance care" with levels "telephone monitoring with or without counseling." Assuming subject observations are independent and identically distributed, a "factorial" decomposition is 
2 + α 0 (1 − R)A
2 + α 1 (1 − R)A 1 A
2 . (1) Note that this decomposition is nonparametric in that it makes no restrictions on the conditional mean of Y . Also we included R in the above decomposition since A ( 
1) 2
can only be assigned to subjects with R = 1 and similarly for A
2 .
A natural approach to screening factors A 1 , A
2 , A (0) 2 would be to conduct inference concerning the coefficients, φ 1 , β 0 , β 01 , β 1 , β 11 . However, this can lead to erroneous conclusions concerning the usefulness of A 1 for at least two reasons. First in the medical/behavioral fields there are a plethora of both known and unknown common causes of R and Y (hence R is prognostic for Y ). For example in alcoholism, common causes of both early response, R and later drinking behavior, Y might be genetic factors, co-morbid depression or homelessness. There are likely many unknown common causes as the field of alcoholism is relatively new. The presence of common causes will lead to a biased assessment of the effect of stage 1 treatment. That is, φ 1 in the above decomposition reflects non-causal biases that occur because we are conditioning on R which is both an outcome of A 1 and a prognostic variable for Y . Robins and Greenland (1994) and Robins and Wasserman (1997) provide numerical examples and discussion. To see this intuitively suppose one of the first line medications leads to more early responders than the other first line medication. Also suppose that, unknown to us, there is a genetic risk factor that if present causes the subject to experience greater perceived benefits from drinking than would be the case otherwise. This risk factor is negatively related to both early response (R) and to later drinking behavior (Y ). Thus the better treatment counteracts the deleterious effect of the risk factor more than the poorer treatment. So nonresponding subjects who received the better treatment are more likely to possess the risk factor than nonresponding subjects who received the poorer treatment. Thus when R = 0 the "treatment effect" φ 1 is too small. Similarly when R = 1 the "treatment effect" φ 1 + ψ 1 is smaller than the actual treatment effect; this negative bias occurs because we are conditioning on early response.
Second even if there are no unknown common causes of R and Y , φ 1 does not reflect the overall impact of A 1 as A 1 may impact Y at least partially by its effect on R (Parmigiani, 2002; Sutton and Barto, 1998, ch. 1; Murphy, 2005) . For both reasons, one does not condition on outcomes such as side effects or other post randomization covariates in comparing one treatment to another in clinical trial analyses (ICH E9, 1999).
These two issues preclude the use of (1) for screening. To our knowledge the former, causal, issue does not arise in the traditional experimental design literature, even in clinical trials with multiple stages. For example, response-adaptive randomization for clinical trials (Hu and Rosenberger, 2006 ) also involves multiple stages of (sequential) decision making, but each stage involves different subjects; that is "sequential" there means decisions on a sequence of subjects not sequential decisions on each subject. Similarly, adaptive designs (Zacks, 1996) utilize a sequence of stages of experimentation with each stage of experimentation also involving different subjects. Since subjects can be generally assumed to respond independently (given membership in the same population of subjects), and the stages involve different subjects, both of the above issues does not occur.
The obstacles discussed above can be overcome by altering the naive definition of main and interaction effects for first stage factors provided by (1) . We provide a definition of the stage 1 effects that reduces to the usual factorial definition of effects when the stage 2 factors do not depend on an outcome (e.g. R) of stage 1 factors. Our definition uses stage 1 effects that are marginal with respect to R. This is consistent with the usual definition of main effects; main effects of a factor are not only marginal over outcomes (except for the primary outcome Y ), and they are also marginal over the other factors (Byar and Piantadosi, 1985) .
Effects in Terms of Conditional Expectations Involving Potential Outcomes
We define the first and second stage effects via potential outcomes (Rubin, 1978; Robins, 1986 Robins, , 1987 . Let a 1 denote a vector of p 1 first stage factor levels, a
2 denote a vector of p 12 second stage factor levels for responders and a (0) 2 denote the vector of p 02 second stage factor levels for non-responders. Also, as is generally the case in screening, each factor has two levels (see below for discussion), coded by values ±1 .
Denote the regime: "provide treatment a 1 in stage 1 and then if an early response occurs provide a 
In words, this is the assumption that a subject's stage 1 outcome remains the same regardless of the stage 2 treatment assignments. Below we use the notation,
That is, the primary outcome of a subject who does not respond (responds) in stage 1, would be the same regardless of which treatment he would have been assigned to in stage 2 had he (not) responded in stage 1. These assumptions allows us to screen factors with the use of experimental designs composed of fewer groups than would otherwise be the case (see the next section). The assumptions hold if the stage 2 randomization is not revealed to the subject and clinical staff until after the occurrence of the stage 1 outcome. However, these two assumptions may be violated if, as part of the protocol, subjects are informed of which stage 2 treatment they will be offered if they respond (do not respond) at stage 1. For example, it may happen that subjects, who know that they will be assigned a rather burdensome stage 2 treatment upon non-response, will adhere more faithfully to their assigned stage 1 treatment than would be the case if they knew they would be assigned a less burdensome stage 2 treatment upon non-response. In this case R a 1 ,a
) may depend on a (0) 2 . Below the stage 2 effects refer to all effects involving at least one stage 2 factor and the stage 1 effects refer to all effects involving only stage 1 factors. The stage 2 main and interaction effects can be defined via as a saturated linear regression model for
in a 1 , a 
where α 1 , β 1 are the second stage main effects and α 2 , β 2 are the second stage interaction effects. We can solve for each of these effects, for example,
2 ,1
2 ,−1
The terms in an linear regression model for (4) can be interpreted as follows. The main effect of one of the p 1 first stage factors represents the main effect of this factor on Y , marginal over the distribution of R (and all other intermediate outcomes in O 2 as well) and in the case in which the other factors' levels are marginalized (marginal with all other factors taking levels ±1 with equal probability). The marginalization with respect to a uniform distribution over the other factor levels is consistent with the definition of factorial effects in experimental design (Wu and Hamada, 2000) . We call this the Uniform Marginalization principle. Note the definition of the stage 2 treatment effects also obeys this principle except the stage 2 treatments are nested within the outcome R and thus we do not marginalize over R in defining the stage 2 effects. That is, 2β 1 in (3) is the difference of two averages, the first average is over levels of the stage 1 factor with the stage 2 factor set to 1 and the second average is over the levels of the stage 1 factor with the stage 2 factor set to −1.
In summary we follow the uniform marginalization principle. The coefficients of terms involving a
in a saturated linear model for (2) provide the definition of the second stage effects. The stage 1 effects as defined as coefficients of terms involving a 1 in a saturated linear model for (4).
Effects in Terms of Conditional Expectations Involving Randomized
Factors.
Suppose we have experimental data in which the factors are randomized according to a distribution on {−1, 1} 
2 } is clearly independent of the collection
2 , A
2 , Y (when R = 1, factor levels given by A
2 are assigned and when R = 0, factor levels given by A (0) 2 are assigned). We make the commonly employed consistency assumption relating the potential outcomes to the observed data (Robins, 1997) .
Consistency assumption: For any values of {a 1 , a
and R = R a 1 .
The randomization of factor levels plus the consistency and ignorability assump- Consider the the mean in (4). The first stage effects are given by a saturated linear model for this mean. This mean can be written as 1 2
2 ,a
Again using the randomization and consistency assumption we obtain that the mean in (4) can be expressed as 1 2
The first stage effects are given by the coefficients in a saturated linear model for the above sum. The above formula is a version of Robins "G-computation" formula (Robins, 1986) 
The first term (6) contains the stage 2 effects. The middle term is composed entirely of nuisance parameters and can be rewritten as
Note that (8) 
2 A 1 , where the first row corresponds to (7), the second row to (8) and the last row to (6).
"Full Factorial" Two-Stage Designs for Screening
Recall the goal of screening is to screen out less active factors; usually two levels of each factor are sufficient for this purpose. In screening the two levels are usually selected to be sufficiently disparate so that one can obtain an effect yet not be unethical. In settings where there is likely to be a downturn in the primary outcome at high levels of the factor, one selects the higher level small enough so that the downturn is thought to be insufficient to eliminate the effect. If necessary, subsequent trials can be used to more fully explore response surfaces.
In a 2 k factorial design, each factor has two levels, and there is a group of subjects assigned to each of the 2 k possible factor level combinations. As discussed in prior sections, the meaning here of the second stage factors vary by the outcome, R, collected during the first stage. Keeping in mind that a subject can only be assigned factors permissible for their first stage outcome, we "stack" the second stage factors in the design and denote this stacked factor by A 2 . As an example suppose that there are two stage 1 factors denoted by A 11 , A 12 and one stage 2 factor for responders and one for non-responders. That is, A Note each row in Table 1 represents a group of subjects; the columns represent the factor levels assigned to each group. The subjects in the first group are assigned A 11 = +1, A 12 = +1. If they respond, they are assigned A The stacking idea used here is also used in group testing (Patel, 1962) in which a column of the design matrix corresponds to a group of factor levels. Note, however, that there the term, two stage factorial experiment, is also used but the meaning is different (in group testing each stage corresponds to a new experiment with new subjects).
The designs considered will be balanced in the sense that for each factor there will be equal numbers of groups assigned the two levels of the factor. This property will play a crucial role in enabling us to ascertain the aliasing between effects. However the designs will not be strictly balanced because the group sizes likely vary. First due to the difficulties in recruiting subjects inherent in clinical trials, the groups of subjects may not be exactly equal in size, and second even if there are equal numbers of subjects in each group (each row) of the design, the number of individuals assigned a particular value of A (1) 2 depends on the response rate. For example suppose A 11 = +1, A 12 = +1 and A 11 = −1, A 12 = +1 results in a 50% response rate whereas A 11 = +1, A 12 = −1 and A 11 = −1, A 12 = −1 results in a 60% response rate. Then if n subjects were initially assigned to each of the 8 groups, we will have .5n subjects in each row 1,2,5,6 assigned A An example of this type of "full" factorial multi-stage design is the recently ended study STAR*D (Fava et al., 2003; Rush et al., 2004 ) for treatment resistant depression. Switches or augmentations of treatment were provided only to those who experienced insufficient response. Furthermore in STAR*D, preference for a switch in medication or an augmentation of medication also lead to differing second stage factors. A second example is provided by ExTENd, an ongoing NIAA funded study of alcohol dependent patients (Oslin, personal communication). In the first stage alcohol dependent patients are provided an opiate antagonist, Naltrexone. Each patient is randomized to one of two criteria for non-response. Then during the following two months the patient's response to Naltrexone was observed. If a patient is responding according to his assigned definition, the patient is randomized to one of two levels of continuing care. On the other hand, if a patient is not responding according to his assigned definition then the patient is randomized to either a switch or augmentation of treatment. Again the second stage factors for patients experiencing a good response are different from the second stage factors for patients experiencing a poor response.
A Screening Analysis for 2 k Factorial Two-stage Experiments
The aim is to screen the stage 1 and stage 2 main effects and interaction effects using data from a 2 k factorial two-stage experiment. In contrast to classical analyses in experimental design (analyses that assume normality and are exact for small group sizes), we consider analyses that are justified by large sample theory (large group sizes) and thus are approximate for small sample sizes. With this viewpoint we interpret a full factorial design as a design in which the factors are independently randomized each with a discrete uniform distribution on {−1, 1}. In large samples the randomization of the factors results in approximately equal sized groups assigned to each row of the design. That is, suppose A 1 and A 2 have discrete uniform distributions on {−1,
2 as the p 12 entries in A 2 corresponding to stage 2 factors for responders and A 
Define X 1 as the random vector composed of a 1, all first stage factors and their two-way and higher order products (2
2 as the random vector composed of all second stage factors for responders, their two-way and higher order products and the all products of these combinations with members of X 1 (2
is defined similarly. For instance, suppose that there are two stage 1 factors denoted by A 11 , A 12 and one stage 2 factor each for responders and non-responders, then X
The decomposition in (6, 7, 8) can be written via a linear model
where β 0 is the vector of all stage 2 causal effects for responders, α 0 is the vector of all stage 2 causal effects for non-responders, ψ 0 is the vector of nuisance effects, φ 0 is the vector of stage 1 causal effects and p(
At the risk of being repetitive, this nonstandard parameterization of the conditional mean isolates the causal effects in contrast to the linear model (exemplified by (1)) decomposition in which φ 1 represents a mixture of causal effects and noncausal correlations. Similar parameterizations have been used by Robins (1997 Robins ( , 2004 and Murphy (2003) to isolate causal effects.
Recall that a parameter is identifiable if different values of the parameter lead to different distributions of {A 1 , R, A 2 , Y } (van der Vaart, 1998). Identifiability in this setting is straightforward.
The above lemma is a direct consequence of two facts. First the conditional means,
times its transpose is given by a block diagonal with blocks,
. These blocks are invertible under the conditions specified in Lemma 1. The details of the proof are omitted.
To utilize (9) in screening estimate p(X 1 ) by forming the average of R for each value of X 1 to obtainp(X 1 ). Conduct a linear regression of Y with covariates:
2 } to obtainφ,ψ,β,α. Note that in contrast to classical screening analyses, these estimators are not orthogonal. This is because homogenous variance (e.g. the conditional variance of Y may vary by factor levels) is not assumed, the groups sizes may not be identical and because (9) is used to define the effects.
Lemma 2 Assume that the variance of Y is finite.
converges to a multivariate normal distribution.
If there are no factors for responders, assume
multivariate normal distribution. The analogous result holds when there are no factors for non-responders.
3. If there are equal numbers of stage 2 factors for responders and non-responders, (e.g. the model in (9) is saturated) the estimatorsφ,α andφ are semiparametric efficient. Also when there are unequal numbers of stage 2 factors for responders/non-responders then if
2 ) when R = 1 and
2 ) when R = 0, the estimatorsφ,α andφ are locally semiparametric efficient.
See Tsiatis (Chapter 4, 2006) for an introduction to and definition of (local) semiparametric efficiency. Note the assumption on the conditional variances in 3. holds under the consistency and ignorability assumptions. This lemma is a special case of Lemma 4 below. Formulae for the variance-covariance matrix is provided in Appendix A.1 along with an asymptotically consistent estimator and the proof of Lemma 4.
2 k−m

Fractional Factorial Two Stage Screening Design
Full factorial designs are useful for exploring a large number of factors with relatively few subjects. However, the number of rows in a full factorial design grows exponentially with the number of factors, thereby resulting in an impractically large number of groups of subjects each assigned a different multi-component treatment. In the clinical trials for mental health and substance abuse, running a large number of groups is prohibitively expensive for a variety of reasons; among which is the need to formulate a cohesive treatment combination for each group, and because the cost in training staff to provide the variety of treatment combinations, one per group. design for the setting in which there are two first stage factors and one second stage factor each for responders/non-responders is 
Fractional Factorial Two Stage Design
2 ). This design has one-half as many rows (groups of subjects) as the full factorial design in Table 1 ; see the examples for more realistic designs. 2 k−m designs are useful because they make use of working assumptions concerning the negligibility of higher order effects. Usually a 2 k−m design is selected by first ascertaining plausible working assumptions concerning the factorial effects. This is done in consultation with the researcher. Wu and Hamada (2000) provide principles that can be used to guide these working assumptions in the absence of scientific knowledge. For example often it is plausible that three way and higher order effects are negligible. Next, the aliasing associated with candidate 2 k−m designs is ascertained; parameters, that is, effects, are aliased when only their sum can be identified (we use the term "aliasing" is used as opposed to "confounding" since the latter term denotes a different concept in causal inference). Lastly the design with the aliasing structure that is most consistent with working assumptions is selected. See Wu and Hamada, (2000) for simple approaches to creating 2 k−m designs.
Identification of Effects
We use a large sample notion of aliasing. Effects will be aliased if only their sum can be identified (operationalized here to mean that we are only able to construct asymptotically consistent estimators of their sum). This is a weaker concept than the finite sample concept of aliasing as discussed, for example, in Wu and Hamada (2000) ; in that setting, effects are aliased if we are only able to obtain an unbiased estimator of their sum.
Defining words are generally used to ascertain finite sample aliasing. Consider the design in Table 2 . The defining word for this design is 1 = A 11 A 12 A 2 (the product of the ±1's across the three columns is equal to 1) this implies, for example, that A 2 = A 11 A 12 (the product of the ±1's in columns 1 and 2 is equal to the ±1's in column 3). It turns out that even though the screening analysis model for a dynamic treatment regime is based on the nonstandard model (9), we will, nonetheless, be able to use the defining words to ascertain the large sample aliasing associated with a particular 2 k−m design. That is, we will use the defining words to specify which parameters or linear combination of parameters are identifiable with data from a 2 k−m design.
In the following we review one useful way to understand the role defining words play in ascertaining which sums of effects are identifiable. To do this we represent conditional means using matrices. Throughout this paper defining words pinpoint which columns in these matrices are identical; the identical columns will then lead to the aliasing.
First consider a brief review of how effects can be shown to be identifiable in the simplest one-stage setting using a 2 two-stage design (recall k = p 1 + p 2 ). As in Section 3, we interpret this as a setting in which each subject is assigned with a discrete uniform distribution to the factor level combinations represented by the rows in the design (this provides a multivariate distribution of {A 1 , A 2 }). The resulting data allows us to identify the conditional mean of Y given R and each of the factor level combinations. As before we can construct a 2 k × 2 k matrix, sayX, with the first column equal to all 1s (the intercept), the next k columns equal to the levels (1s, −1s) for the k factors (the main effects) and the remaining 2 k − 1 − k columns equal to products of the k columns (all two way and higher order interactions). PartitionX into two matricesX 1 (composed of the intercept column, columns equal to the levels of the first stage factors and all products of these columns) andX 2 (composed of the columns equal to the levels of the stacked second stage factors, and all products between these columns and the non-intercept columns ofX 1 ). BothX 
for each value of R. The above is a matrix version of (9) . Indeed the connection be-
2 , X
2 } and the matrices, {X 1 ,X
2 ,X
2 } is as follows. Recall the random vectors {X 1 , X
2 } are constructed by including a vector of all ones in X 1 and then taking all products of random variables in
is formed by taking products between random variables in A 
2 . The row expectations of Y conditional on R = 1 (or R = 0) and conditional on the values of A 1 , A 2 are equal to
Throughout we call X 1 the stage 1 matrix and
2 ) the stage 2 matrix for nonresponders (respectively responders). Each row of X 1 , X 
If the defining words indicate that there are one or more columns common to both X 1 and X (1) 2 or to both X 1 and X (0) 2 then for each common column assume 3a) the nuisance effect(s) (ψ parameters) associated with the column are zero, or 3b) the stage 2 effects (β, α parameters) associated with the column in X
2 and X (0) 2 are zero, then the defining words can be used to ascertain aliasing of the parameters as follows.
1. If the defining words indicate that are multiple copies of a column in the stage 1 matrix X 1 , but this column does not appear in X
2 or X
2 then only the sum of the φ coefficients associated with these columns are identifiable. That is these stage 1 effects are aliased.
2. If the defining words indicate that are multiple copies of a column in the stage 2 matrix X
2 (X
2 ), but this column does not appear in X 1 then only the sums of the β (α) coefficients associated with these columns are identifiable. That is, these stage 2 effects for responders (non-responders) are aliased. ) 2 also appears in the stage 1 matrix X 1 then under assumption 3a) the sum of the associated β and φ parameters is identifiable and the sum of the associated α and φ parameters is identifiable. Under assumption 3b) the associated stage 2 parameters are zero. The sum of the associated stage 1 parameters is identifiable.
See the Appendix A.1 for a proof of Lemma 3. We restrict ourselves to 2 k−m designs for which either 3a) or 3b) holds for any common stage 1 and stage 2 columns in X 1 and X 2 of Lemma 3. This is a formal assumption on the form of the underlying row expectations. The use of designs in which this formal assumption is violated produces aliasing that is not easily discernable by the defining words(see Section A.3 in the Appendix for an example) between effects. Note that one can choose a design in which X 1 and X 2 do not share a column (see example 1 in Section 4) and thus formal assumptions are not required.
In summary, prior to selecting a particular 2 k−m design, we formulate working assumptions concerning the effects. Then we use Lemma 3 to select a design for which all but one of the parameters in each set of aliased effects is thought to be negligible.
Screening Effects
Of course we cannot fit the model (9), as is, since the 2 k−m design does not provide Y outcomes for all 2 k values of {a 1 , a 2 } (the omitted outcomes correspond to the omitted rows in the design). To permit a regression model we rewrite (9) in terms of aliased effects.
Recall that each column in stage 1 and stage 2 matrices X 1 , X
2 and X
2 represents a variable in the vectors X 1 , X
with these parameters from X 1 and retain the variable that is associated with the one effect that, according to the working assumptions, may be non-negligible. Name the resulting vector Z 1 . Define U 1 = Z 1 (U 1 can be used to estimate of the response rates; see below). The same procedure is followed if multiple stage 2 parameters for responders are aliased (resulting in vector Z
2 ) and if multiple stage 2 parameters for non-responders are aliased (resulting in vector Z 3. If some of the nuisance, ψ, parameters are assumed to be zero (via assumption 3a) then create Z 3 from Z 1 by eliminating variables in Z 1 with an assumed zero valued ψ parameter. Otherwise Z 3 = Z 1 .
4. Again if some of the nuisance, ψ, parameters are assumed to be zero, then using the defining words identify the variables associated with the common columns in X 1 , X
2 . For each of these columns, group the names of the three variables associated with the column and remaining in Z 1 , Z We obtain
where the primes on the regression coefficients indicate each may represent a sum of aliased effects. Using the working assumptions the regression coefficients can be labeled as corresponding to particular first stage effects, nuisance effects, a second stage effects for responders and second stage effects for non-responders.
To conduct the screening we estimate p(U 1 ) for each value of U 1 in the design by the proportion of responders assigned that value to obtainp(U 1 ) (p(U 1 ) can be formed from a saturated regression of R on U 1 ). The screening analysis is a regression The proof, and an asymptotically consistent estimator for the variance-covariance matrix, is provided in Appendix A.1. In general the model (12) should be saturated. Exceptions occur when more formal assumptions are made than is necessary (see example 3 for an illustration). Or when according to the design, there are one or more stage 2 factors (only for responders or only for nonresponders) with levels completely crossed with the levels of all other factors (e.g. these stage 2 factors are randomized independently of the remaining factors and they are not stacked with other factors in the design). For completeness Appendix A.1 also supplies an estimating function yielding semiparametric efficient estimators for use in the case when (12) is not saturated.
Sample Size Considerations
In determining an appropriate sample size we consider two issues. First we assume that the primary goal is to assess the activity of all first stage and second stage main effects. Thus the study should be powered to achieve this goal. Second if we are to assess main effects for responders (respectively non-responders) then we want to reduce the probability that a row with no responders (respectively no nonresponders) may occur. To choose the sample size N , we make the following rough approximations. We assume that our formal assumptions, if any, are correct and that the residual variance is equal across the 2 k−m rows in the design, say σ 2 . Ignoring the variance due to the estimation of the response rate, the variance-covariance matrix of the estimated effects (see Appendix
where SNR is the desired effect size divided by σ and p min , p max are minimal and maximal response rates (across the 2 k−m rows) and z u is the (1−u)th standard normal percentile.
Suppose there are stage 2 components for both responders and non-responders. If the SNR is very large then the recommended row size will be so small that the chance of a group (corresponding to a row in the design) occurring with no responders or no non-responders is too high. Given the response rate p and group size n = N/2 k−m , the chance that a group of this type will occur is 1
To reduce the chance of such groups we find the smallest n for which the above probability is smaller than a cutoff (in the simulations we use .01). To set the group size we use the maximum of the above number times 2 
Examples
In this section we illustrate potential 2 k−m designs and associated working and formal assumptions. Again, we highlight that we are able to explore a relatively large number of factors with relatively few rows and the proposed analysis screens causal effects. Consider a study with four stage 1 factors: I (speciality or general practice clinic), B (adjunctive therapy to improve adherence: yes/no), C (counseling: intensive/less intensive) and T (level of staff training: high/low). All individuals are offered medication. There is one second stage factor for early non-responders F 2 (switch or augment medication) and one second stage factor for early responders G 2 (telephone disease management yes/no). Suppose that working assumptions are that all effects except the main effects of the factors and the two way interactions CG 2 , T G 2 , BF 2 , T F 2 and BC are expected to be negligible. Recall, these working assumptions are used to guide the choice of the 2 k−m , but are not necessarily assumed true in the screening analysis. designs. In the Design 3 below we allow for an additional stage 2 factor which is applicable only for the non-responders. This factor, denoted by H 2 , denotes the presence/absence of an additional behavioral contingency (with the goal of improving longer term adherence) and we expect that the presence of the additional behavioral contingency will interact with medication (F 2 H 2 ). Here a 2 6−2 design is discussed. Design 1: Suppose we do not want to make any formal assumptions (e.g. 3a) concerning the negligibility of nuisance effects or 3b) stage 2 causal effects). The natural choice is a design that completely crosses the stage 2 factor levels with the stage 1 factor levels. That is, in design 1 the stage 2 factors are crossed with a 2 (Table 2) . The defining word indicates that the stage 1 and stage 2 matrices X 1 and X
(or X
2 ) do not share columns and thus stage 2 effects are not aliased with nuisance effects (or stage 1 effects). As a result the aliasing follows directly from the defining word (e.g. the two way interaction BC is aliased with the two way interaction IT , and since IBCT G 2 = G 2 , the two interaction T G 2 is aliased with the interaction IBCG 2 , and so on). Note that this design is consistent with the working assumptions in that all of the interesting effects are aliased with effects that are thought to be negligible.
The screening analysis consists of a regression of Y on
. This is a saturated model. Recall that due to the nonorthogonality of the predictors, omitting further terms (columns) from this model is equivalent to making formal assumptions.
An advantage of this design is that no negligibility assumptions on the nuisance parameters (ψ's) need be made. However, this design is somewhat wasteful. Consider the aliasing. Two way stage 1 interactions were aliased with each other. A better design would not alias two way interactions between stage 1 factors.
Design 2: Suppose that we are willing to make the formal assumption that there are no three way or higher order stage 2 interactions (α and β regression coefficients of interactions between a stage 2 factor and two or more stage 1 factors are 0), and that there are no four way or higher nuisance interactions involving R and stage 1 factors (ψ regression coefficients of interactions between R and three or more stage 1 factors are 0). Consider a 2
5−1
design with defining word
with F 2 and G 2 stacked (so another expression for the defining word is IBCT G 2 = 1). The design is provided in the Appendix, Table A.1. As in design 1, the stage 2 factors are stacked in the same column of the design matrix. The defining words indicate that under the formal assumptions, none of the stage 1 main effects or two-way interactions are aliased. Also potentially active stage 2 effects, such as CG 2 , can also be estimated since the nuisance effects associated with the same column in the stage 1 matrix X 1 , (here the four way interaction between R and IBT ) are negligible. And potentially active nuisance effects such as the three way interaction between R and IB can be estimated since these nuisance effects are associated with the same column in the stage 2 matrices X 2 ) as negligible stage 2 effects (here CT G 2 and CT F 2 ). To screen the factors using data from design 2, we regress Y on
where Z 1 =
[1, I, B, C, T, BC, IB, IC, IT, BT, CT ], Z
. This is a saturated model. As before, omitting terms in this model is equivalent to making further formal assumptions. Using the defining words we deduce that the three way and higher order stage 1 effects are aliased with stage 2 effects. For example the β coefficient of G 2 is actually estimating the sum of main effect of G 2 and the four-way interaction ICBT and the β coefficient of BG 2 is estimating the sum of the BG 2 interaction and the three way interaction ICT .
To summarize, in design 2, the two way interactions between stage 1 factors are not aliased with one another as was the case in design 1. However formal assumptions on higher order nuisance parameters and on higher order stage 2 effects are made. That is, we assumed that there were no four way and higher order interactions involving R and first stage factors and no three way and higher order interactions involving stage 2 factors.
Design 3: In order to illustrate some of the more subtle considerations, consider the inclusion of an additional stage 2 factor H 2 (behavioral contingency to improve medication adherence) that is only assigned to non-responders (R = 0). Further suppose we are willing to make stricter formal assumptions concerning the nuisance parameters than made in constructing design 2. In particular the formal assumptions are that there are no three way or higher nuisance interactions involving R and stage 1 factors and that three way and higher stage 2 causal effects are negligible. Recall that the working assumptions are that all effects except the main effects of the factors and the two way interactions T G 2 and F 2 and G 2 stacked (so we could express the above with a G 2 instead of F 2 ); furthermore note the product of these two defining words yields 1 = IBCH 2 .) In contrast to designs 1 and 2, not only the experimental design but also the choice of the regression model determines the aliasing (we use step 4 of the algorithm in Section 4.2 to determine the aliasing). Indeed we have a choice of several regression models that can be used to screen the factors each corresponding to different aliasing. Using the steps in Section 4.2 we see that one possibility is to use Z 1 = [1, I 
, B, C, T, IB, BC, BT, IBC, IBT, BCT
in the screening regression. Using the defining words, we can deduce the aliasing. For example since the defining words indicate that G 2 = F 2 = ICT and ICT has been omitted from X 1 , we have that the β coefficient of G 2 is the sum of the main effect of G 2 and the three way interaction ICT ; similarly the α coefficient of F 2 is the sum of the main effect of F 2 and the three way interaction ICT . Note that the defining words indicate that BF 2 = BG 2 = T H 2 = IBCT and we included only BF 2 , BG 2 in the regression thus the α coefficient of BF 2 is the sum of the two way interactions BF 2 , T H 2 and the four way interaction IBCT whereas the β coefficient of BG 2 is estimating the sum of the two way interaction BG 2 and the four way interaction IBCT . In general, given the formal assumptions, the defining words along with the choice of Z 1 , Z ( 
1) 2
and Z (0) 2 result in the aliasing: 
Both of the two screening analysis models discussed above have 30 parameters and hence are not saturated models. If desired we could fit a saturated model by adding two nuisance interactions to Z 3 , IBT and BCT . These two nuisance interactions were needlessly assumed to be negligible in the formal assumptions. For example, from the defining words, note that the column associated with IBT is the same as the column associated with the three way stage 2 interactions IF 2 H 2 , T CH 2 and BCF 2 all of which were assumed to be negligible. That is we made both assumption 3a and 3b in Lemma 3 instead of one or the other. Estimation of these two effects acts as a check on the formal assumptions since under the formal assumptions these two nuisance effects are zero.
To summarize, if we use design 3, we are able to screen an additional factor (H 2 ). However in contrast to designs 1 and 2, formal assumptions concerning the negligibility of lower order nuisance parameters are made. That is, we assumed that there were no three way and higher order interactions involving R and first stage factors and no three way and higher order interactions involving stage 2 factors.
Simulation Results
Extensive simulations were conducted so as to evaluate the proposed analysis, examine the impact of violations of the formal assumptions and examine the impact of rows with no responders (or no non-responders) on the analysis. We are particularly interested in mental health settings such as the treatment of major depression and substance abuse in which response (absence of symptoms) rates to initial treatment are around 50 to 70% as a result the simulations below use initial response rates in this range. Due to the sample size requirements, usually when response rates are high, only factors for responders are investigated and when non-response rates are high, only factors for non-responders are investigated.
The findings were as follows. First when the formal assumptions hold, the standard errors performed well and the Type 1 error is as planned. In general the sample size calculations depend on the group with the smallest proportion of non-responders (or responders). As a result the sample size calculations are conservative and the power to detect active stage 1 main effects and stage 2 main effects is higher than the nominal value. Simulations with both normal and non-normal error distributions such as a t-distribution with 3 degrees of freedom were also conducted; this did not substantially alter the results. When the formal assumptions are violated (e.g. effects assumed negligible in the formal assumptions are not negligible) there is a surprising degree of robustness; that is, the bias is of smaller magnitude than would be expected. Also when one or more rows contain only responders, fitting an analysis model that omitted some active effects led to relatively robust estimators of the remaining effects. This robustness is discussed at greater length following simulation 2. We present three simulations that exemplify the above findings.
The simulations below use Design 2 (see Table A .1). In this example the formal assumptions are that there are no three way or higher order stage 2 interactions and there are no four way or higher order nuisance interactions involving R and stage 1 factors. In the simulations provided below, R is generated using a response rate given by logit E[R|F 1 ]) = .6 + .1I + .1B + .1C + .1T . This results in response rates varying from .55 to .73 across the 16 rows.
In the simulations, Y is normally distributed with residual variance, σ 2 , set to 1. We present results with SNR (effect size/residual variance) equal to .25 or .35 units per standard deviation (in the behaviorial sciences .15 is considered a moderate SNR and .35 a large SNR, see Cohen, 1988 ). In the simulations, active main effects are equal to the SNR×σ, active two way interactions are equal to SNR×.5 × σ and active three way interactions are set equal to SNR×.25 × σ. These settings are consistent with the Hierarchical Ordering Principle (Wu and Hamada, 2000, pg. 112) which states that the lower order effects are more likely to be important than higher order effects and effects of the same order are equally likely to be important (this principle is used in the absence of domain knowledge indicating otherwise). Throughout the active causal effects are all main effects and the interactions IB, IC, IG 2 , T G 2 and T F 2 ; this means that the working assumptions are not all correct (the working assumptions are that only the main effects of the factors and the two way interactions T G 2 , T F 2 , CG 2 , BF 2 and BC are likely to be active).
We used the recommendations provided in Section 4 to determine the row size required to detect a given SNR at 90% power with a 10% Type 1 error rate. For these simulations, p min = .55 and p max = .73; this wide range of early response rates is extreme for the mental health/substance abuse fields however it allows us to illustrate the issues. Interesting effects are tested using a Type 1 error rate of .1 (no correction for multiple tests) and the remaining effects are tested using a overall Type 1 error rate of .1 (using a Bonferroni correction). Table 3 provides an example of simulation results when the formal assumptions are correct. Note that there are 9 effects that according to the working model should be negligible. Given an overall error rate of .1, the empirical error rate should be around .011 and this is the case as can be seen by the rows labeled IT , BT , CT , BG 2 , IF 2 and CF 2 . Similarly the empirical Type 1 error rate for the interesting effects should be around .1 and this can be seen by rows labeled BC, CG 2 and BF 2 . Note the power to detect the main effects is high (either 1.0 or .96). The high power is due to the conservatism used in selecting the group size. Recall that the response rates per group range from a low of .55 to an high of .73. The group sizes are chosen then to achieve the power .9 to detect stage 2 effects for non-responders when the non-response rate is .27. Since only one of the groups exhibits this low non-response rate, the group sizes are conservative, resulting in higher power. In simulations with a constant response rate across all 16 groups (not shown here) the power to detect a main effect for stage 2 non-responders varied from around .88 to .94 depending on the simulation.
The next simulation illustrates the robustness of the method to violations of the formal assumptions. Indeed suppose in violation of the formal assumptions there are active three way stage 2 effects for responders. The results in Table 4 are surprisingly good; the results in this table would be expected if the interactions involving R were zero (no nuisance interactions). To see this, recall the defining words for this design are 1 = IBCT G 2 (equivalently 1 = IBCT F 2 ). Thus, for example the column in the stage 2 matrix X (0) 2 matrix associated with CT F 2 is the same as the column associated with IB in X 1 . If the nuisance interactions were zero (they are not), then we would be able to use the defining words to provide the aliasing. If the coefficient of the interaction (R − E[R|A 1 ])IB were zero then we would expect that estimators of the stage 1 interactions such as IB will estimate this interaction plus the product of the response rate times the effect of CT G 2 plus the non-response rate times the effect of CT F 2 . In this case, this is .175+ response rate(.0875)+ non-response rate(0). If we use the average non-response rate (here .64), this yields .231 which is close to the average estimated effect for IB. Similar statements can be made for remaining stage 1 two way interactions. This robustness is explained by the fact that the response rates vary only from .55 to .73 across the groups. As discussed in Section 4, the less the response rates vary, the closer the predictors are to being orthogonal. Thus the estimators of the effects are approximately uncorrelated (the off diagonal elements of the correlation matrix are small-in this simulation the maximum correlation in absolute value is .12 and the average of the absolute value of the correlations is .03). Thus as long as the response rates do not vary greatly (as is the case in many areas of mental health and substance abuse) one can expect this robustness. Similar results hold when the formal assumptions concerning the nuisance effects are violated (not shown here).
Also this simulation, by chance, did not result in any samples with one or more groups containing only responders. However this can happen and did happen in other simulations (not shown). Indeed when SNR= .35 the group sizes had to be adjusted upwards to ensure that the probability that one or more of the 16 groups in the design will have no non-responders is not too low (low is arbitrarily chosen to be .01; see Section 3.2). Even with this adjustment, a simulation size of 1000 samples will sometimes include some samples in which groups with no responders occur. If in a given data set, however, some groups (e.g. corresponding to rows in the design) contain no responders we fit a model using the working assumptions, that is,
The working assumptions are incorrect thus the omission of active effects biases the estimated effects. To examine the degree of bias we conducted a simulation in which the groups corresponding to the rows of the design were sufficiently small so that the chance of one or more groups with all responders was likely; in effect we simulated many samples saving only those that had one or more groups with all responders. Table 5 reports the results for 729 such samples. As with simulation 2, this simulation demonstrates robustness of the analysis method to the omission of active effects. Note that both the bias of the estimators and the quality of the standard errors is poorest for the stage 2 effects for nonresponders. This is not surprising as many rows will have few non-responders (if at all).
Discussion
This paper provides a first approach to a screening experiment in the development of dynamic treatment regimes. However there are many open problems.
First there is the question of how to construct the optimal experimental designs. A first thought might be to utilize the maximum resolution criterion (Box and Hunter, 1961 ) or its refinement, the minimum aberration criterion (Fries and Hunter, 1980) . Note that the design in example 1 has only resolution IV whereas the design in example 2 has higher resolution (V). However it is not necessarily true that the example 2 design is to be preferred as the example 2 design requires formal assumptions whereas the example 1 design does not. More work is required to appropriately incorporate the roll of the formal assumptions into methods for comparing these two level designs. Another open question is how best to choose among the multiple analysis models; because of the non-orthogonality of the predictors, different models result in tests with different powers. A coherent strategy for choosing among these different analysis models is needed.
Furthermore this paper has not discussed potential secondary analyses that might be used with data from a 2 k−m design. Such analyses might consider how best to construct the decision rules (using the variety of covariates). The methods of Murphy Another open area is how one might best conduct screening experiments when it is thought that an outcome in the first stage of treatment (e.g. adherence to initial treatment) will likely interact with available stage 2 treatments. When interactions between a variable and a treatment are suspected one often blocks on the variable as to ensure adequate representation of the variable in each row; however this is not possible here as variables such as adherence are outcomes of the stage 1 factors and are thus unknown at the time individuals are assigned to rows. A fifth open area includes how one might seamlessly move from a screening experiment to further experiments. Subsequent experiments would be conducted using only the important components from the screening experiment, to ascertain the best dose of continuous components and/or to further investigate interactions always with the goal of optimizing patient outcome. The procedure is frequently called response surface methodology (Box, Hunter and Hunter, 1978) . Lastly, such experiments might then be followed by a two arm randomized trial with one arm assigned the constructed multi-component dynamic treatment regime and the other arm an appropriate comparison. A series of such experiments was proposed by Collins et al. (2005) in the behavioral field and this experimentation strategy is currently being employed (Strecher, P50 CA101451, personal communication).
Lastly a natural and important concern is that some rows will have only nonresponders (or responders). As discussed previously our interest is in mental health settings such as the treatment of major depression and substance abuse in which response (absence of symptoms) rates to initial treatment are around 50 to 70%. In some areas of substance abuse response rates can be quite low (J. Sacks, personal communication), say around 10-20%. Our experience is that, in these cases, researchers do not investigate factors for early responders (e.g. all early responders are assigned to the same treatment) and instead focus on multiple factors for nonresponders. In these cases, the use of a sample size adequate to ensure sufficient numbers of non-responders may result in rows with no responders, but this will have no ill effects.
In general, if scientists really want to study factors for both responders and nonresponders then the study should be sized (see Section 3) to reduce the chance that a row results in only responders or non-responders. Nonetheless such rows may occur by chance or because the response rate used in designing the study was grossly incorrect. In the simulations, we then fit a model with only the effects assumed likely to be active (e.g. according to the working assumptions). In general the analysis involves assessing the fit of various parsimonious models. These analyses are akin to that for an observational study in that one seeks to fit a well fitting model, without overfitting, and correct inference relies on the formal assumption that the omitted effects are unimportant. However, unlike the observational study the use of randomization to factor levels provides higher quality causal inference as compared to an observational study. Furthermore, since the screening study will be followed by further experimental studies (either a two group randomized trial or response surface studies) there will be opportunities to correct significant misinterpretations.
have for R = 0, 1,
where the defining words specify the common columns in X 1 , X
2 and X . We group terms in the above display so that only unique columns remain. First if a column occurs k times in X 1 then delete k − 1 of the columns and sum all terms in ψ 0 and φ 0 associated with the column. Each sum becomes the coefficient of the remaining column; all of the remaining entries in ψ 0 , φ 0 remain the same. This process is repeated until all columns are unique resulting in a matrix Z 1 and two vectors of coefficients ψ 0 , φ 0 for which X 1 ψ 0 = Z 1 ψ 0 and X 1 φ 0 = Z 1 φ 0 . We follow a similar procedure for the two stage 2 matrices resulting in X 2 . This is because such a column would have been assumed to either have a ψ 0 coefficient or α 0 , β 0 coefficients equal to zero by assumptions 3a), 3b) respectively. There may, however, be one or more columns which are common to all three,
2 , matrices. Note the above discussion implies these columns are not in Z 3 . This setting corresponds to item 4 under Lemma 3. To obtain regression coefficients that are identifiable, we need to eliminate each common column from one of these three matrices. To see this consider one such common column, z which is, say, the ith column of Z 1 , the jth column of Z (1) 2 and the kth column of Z (0) 2 . This column contributes zφ 0i + Rzβ 0j + (1 − R)zα 0k to E [Y|R] . We can write this sum in three ways corresponding to how we delete this column from one of the three matrices:
If we delete z from Z 1 then we will be able to identify the sum of the associated stage 1 and stage 2 effects; if we delete z from Z
(1) 2 then we will be able to identify the sum of the associated stage 1 effect and the stage 2 effect for responders and also the difference between the stage 2 effect for non-responders and the stage 2 effect for responders; if we delete z from Z (0) 2 then we will be able to identify the sum of the associated stage 1 effect and the stage 2 effect for non-responders and also the difference between the stage 2 effect for responders and the stage 2 effect for non-responders.
Note the assumption that 
Multiply all terms in both of these equations by Z 
Identifiability of φ 0 , α 0 and β 0 follows from the fact that there are no columns common to all three of the matrices.
In there are no factors for responders remove X
2 β 0 from (13) . Then follow the above arguments. Similarly if there are no factors for non-responders remove X (0) 2 α 0 from (13) and follow the arguments above.
Below we show that Σ γ is invertible. Again standard arguments can be used to show that
where
A consistent estimator of the asymptotic variance-covariance matrix is provided by replacing Σ γ byΣ γ , Σ γ,η byΣ γ,η , Σ η,η byΣ η,η , η 0 byη, γ 0 byγ and the operator E by E N in the above. To improve the accuracy of the variance estimators when samples are small, we recommend adjusting the formula for the number of estimated parameters. That is multiply the estimated variance-covariance matrix by N/(N − q γ − q η ) where q γ is the dimension of γ and q η is the dimension of η.
Proof that Σ γ is invertible: Construct the matrices Z 1 , Z 3 , Z
2 , Z 
where the 0's denote conforming matrices with all entries equal to zero. Then 2
We show thatZ is of full rank. This combined with the assumption that the response probabilities are bounded away from both 0 and 1 will imply that Σ γ is invertible. Note thatZ will have less than 2(2
) rows) if there are unequal numbers of factors for responders and non-responders and/or unnecessary formal assumptions have been made. We can add columns toZ by adding back in columns to Z 3 associated with nuisance effects that did not necessarily need to be assumed zero (see example 3 for an illustration). Suppose there are fewer stage 2 factors for responders than for non-responders; this means that some of the stage 2 factors for non-responders are not stacked with a stage 2 factor for responders. Add the columns in Z ) matrixZ is of full rank then certainly any subset of columns is also full rank. Hence it suffices to prove that Z is of full rank in the case when it is square (has 2(2 k−m ) columns).
NextZ =Z 1 +Z 2 wherẽ
Z 1 is easily shown to be of full rank, once one identifies common columns in Z 3 , Z 1 , Z
2 , Z
2 . Note by assumption there are no columns common to Z 3 and Z are proportional to the matrix:
where q 3c is the number of common columns between Z 3 and Z 1 and q 3u is the number of columns unique to Z 3 . In this we reordered the columns of Z 3 and Z 1 so that the common columns appear first. Next becauseZ 1 is of full rank and square (thus invertible) we can write,
Using the formula for the first q 3 rows of Z T 1Z 1
−1
we find that the term in parentheses is proportional to a matrix of the form
where U is of dimension 2(2 k−m )−q 3 ×q 3 . This square matrix has nonzero determinant and is thus invertible.Z is invertible.
Efficiency: First we derive the semiparametric efficient score. Then we discuss how one can use this score to produce a locally semiparametric efficient estimator of γ . Lastly we prove that in the saturated model the estimators are semiparametric efficient and that under an additional assumption on the variances (this assumption is provided in Lemma 2) certain unsaturated models will also yield semiparametric efficient estimators.
Semiparametric Efficient Score: The semiparametric model is given by
) and η belongs to R q η (q η is equal to the number of rows in the 2
Recall the efficient score is the residual of the projection of the score vector for {γ , η} onto the nuisance tangent space, Λ. Equivalently the efficient score is the projection of the score vector for {γ , η} onto Λ ⊥ . In this case the latter is easier to compute. Tsiatis (Section 4.5, 2006) proves that (a 1 , r, a 2 ) ∀ g arbitrary q-dimensional functions of {a 1 , r, a 2 
}}.
Because R is a binary random variable, members of Λ 3 also have a simple form:
We have that the efficient score must be of the form, 
Similarly, assuming that
.
If we denote the scores for γ , η, by S γ , S η , respectively we see need only calcu- 
for all values of a 1 , r, a 2 , η, γ (recall u and z are functions of these). Differentiating both sides of the first two equations with respect to γ we obtain
Differentiating both sides of each of the last two equations with respect to η results in:
. Putting these results together we obtain the efficient score for (γ , η):
Although we did not show this above, the smoothness assumptions imply that the estimators {γ ,η} are regular, asymptotically linear estimators (see Tsiatis (2006) for definitions). If Σ ef f were singular then no regular, asymptotically linear estimators can exist (Chamberlain, 1987) . Thus Σ ef f must be invertible. Furthermore for any regular and asymptotically linear estimator, say ((γ )
, and a qdimensional vector, a, we have that a lower bound on the asymptotic variance of
A Semiparametric Efficient Estimator: To construct a semiparametric efficient estimator we employ the efficient score, S ef f as follows. As before we assume that
First use the method described in the body of the paper (and above in this Appendix) to produce consistent estimatorsγ ,η. Next setσ
) to be the sample variance of the residual (Y − Z(η) Tγ ) for responders (respectively, non-responders) for each group (each row) of the design. Solve (15) for γ , η to obtainγ ef f ,η ef f . Standard arguments can be used to show that
as N → ∞. Semiparametric Efficiency of {γ ,η}: In general the model(12) should be saturated; this is because each variable associated with an effect (or one of its aliases) will occur in two vectors, either in Z 1 and Z 3 or in Z 1 and Z 2 (Similarly (9) will generally be saturated as well). An exception to this pattern (and thus the model will not be saturated) occurs if there are unnecessary formal assumptions; that is both assumptions 3a) and 3b) are made concerning the effects associated with a particular column in Lemma 3 rather than just one of these. In this case the "Algorithm for Constructing the Regressors for Use in the Screening Analysis" of Section 4.2 will remove too many variables from Z 3 .
Assuming that no unnecessary formal assumptions are made, the only other reason why (12) (or 9) will not be a saturated model is if there is a stage 2 factor for only responders (or only non-responders) and the design specifies that this factor's levels are crossed with the levels of the remaining factors (e.g. this factor is independent of the remaining factors). In this latter case effects involving this stage 2 factor can only be aliased with other effects involving this stage 2 factor. As a result each variable associated with effects of this stage 2 factor (or one of its aliases) can only be included once and only in Z (1) 2 . However under the assumption that
2 )] = 1 we show that in this non-saturated case, {γ ,η} is locally semiparametric efficient. The adjective, "locally" is used because the semiparametric efficiency holds if this assumption holds and otherwise not.
First we prove that {γ ,η} is semiparametric efficient when (12) is a saturated model. For simplicity suppose there are stage 2 factors for both responders and nonresponders. Assume
This means that the probability of P [{min a 1 ,r,a 2σ a 1 ,r,a 2 > 0}∪{min u 1 |u
Thus we assume in the sample the proportion of responders in each of the 2 k−m groups is not equal to one or zero. In this case we prove that {γ ,η} = {γ ef f ,η ef f }.
is zero as well.
To see this suppose that there are ν unique values of U 1 in the design (ν ≤ 2 k−m ). Then,
where U 1 is a ν × ν matrix with each column corresponding to a realization of U 1 , D is a diagonal matrix with ith entry equal to E N [R1 U 1 =u 1i ] andR is the ν dimensional vector of observed response proportions. Since E N U 1 (R − U T 1η ) = 0, U T 1 and D are invertible, we have thatη satisfiesR = U 1η . Since we can write E N U 1
in a similar matrix formulation (only the diagonal matrix is altered) we see that this formula is equal to zero as well. . Using the same proof as used in Lemma 4 to show thatZ is full rank, we can show thatẐ is full rank as well (and hence invertible). Define D 1 to be a diagonal matrix with ith diagonal entry equal to the proportion of responders in the ith group multiplied by the group size. Similarly define D 0 to be a diagonal matrix with ith diagonal entry equal to the proportion of non-responders in the ith group multiplied by the group size.
We can write 0 = E N Z(η) Y − Z(η)
Thus in the saturated model,γ as matrices times the above difference we have these two terms are zero as well. Combining the above with the results forη, we have that when the model is saturated and the sample is sufficiently large so that the response rates in each of the 2 k−m groups are neither zero or one,γ =γ ef f andη =η ef f .
Next we prove that in the non-saturated model, {γ ,η} will be locally semiparametric efficient if 1) no unnecessary formal assumptions are made (assumptions 3a and 3b are made concerning the effects associated with a particular column in Lemma 3 rather than just one of these) and 2) there is a stage 2 factor for responders (or non-responders) that is independent of the remaining factors. 
As before the invertibility ofẐ implies that the last term in parentheses is equal to zero. Because we can express both 
A.2 Designs
Design 2 is provided in Table A.1; in this design the main effect of the second stage factor is aliased with a four way interaction between first stage factors. The defining word is I = IBCT F 2 . 
A.3 Aliasing and The Formal Assumptions
Here we provide a simple example of how the aliasing becomes difficult to interpret when the formal assumptions do not hold. Suppose there are two factors at stage 1 and one stage 2 factor for responders. We are interested in the main effects of these factors and we are willing to make the working assumption that there are no interactions. Suppose we are willing to make the formal assumption that all effects of R (including interactions between R and the first stage factors) are negligible. We use the experimental design in Table 2 Suppose that it is known that ψ j = 0, j = 1, 2, 3. However we do not know whether any of the remaining parameters are zero or not. The experimental design in Table 2 11 ∈ {−1, 1}, a 12 ∈ {−1, 1} and r ∈ {0, 1}. So from data resulting from the experimental design in Table 2 we can identify the eight quantities such as: φ 0 + ψ 0 , φ 1 + η 1 ψ 0 , φ 2 + η 2 ψ 0 , φ 3 + η 3 ψ 0 , ψ 0 + β 3 , β 0 , β 1 and β 2 . The above nonlinearity in parameters makes it difficult to interpret the identifiable quantities involving the φ j 's. More complex designs result in similarly uninterpretable quantities. In summary, to maintain interpretability, we consider experimental designs that do not alias a potentially active stage 2 effect with a potentially active nuisance effect.
